2-Fluorodeschloroketamine

2-Fluorodeschloroketamine, or 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone, is classed as an arylcyclohexylamine drug. Arylcyclohexylamines drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. 2-FDCK contains a phenyl ring bonded to a cyclohexane ring substituted with a ketone group (cyclohexanone). An amino methyl chain (-N-CH₃) is bound to the adjacent alpha carbon (R₂) of the cyclohexanone ring. Additionally, the phenyl ring is substituted at R₂ with a fluorine group.

2-Fluorodescholoroketamine is a chiral molecule and is often produced as a racemate. Des- is a prefix used in chemistry to denote the absence of a functional group (in this case "chloro") hence 2-FDCK is named for containing a fluorine substitution at its phenyl ring rather than the chlorine which is found in ketamine.

Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other arylcyclohexylamine dissociatives such as DCK and ketamine. With this in mind, 2-Fluorodeschloroketamine is thought to act as an NMDA receptor antagonist.

NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance's equivalent of the “K-hole.”

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

• Erowid Experience Vaults: 2-Fluorodeschloroketamine

The toxicity and long-term health effects of recreational 2-Fluorodeschloroketamine use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-Fluorodeschloroketamine has very little history of human usage. Anecdotal evidence from people who have tried 2-Fluorodeschloroketamine within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this drug.

Dependence and abuse potential

As with other NMDA receptor antagonists, the chronic use of 2-Fluorodeschloroketamine can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-Fluorodeschloroketamine develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 2-Fluorodeschloroketamine presents cross-tolerance with all dissociatives, meaning that after the consumption of 2-Fluorodeschloroketamine all dissociatives will have a reduced effect.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 2-Fluorodeschloroketamine seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine but to a lesser extent. This is because 2-Fluorodeschloroketamine is a little more potent than ketamine, meaning that less of the drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and include:

• Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
• Urinary urgency - This can be described as a sudden, compelling need to urinate.
• Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
• Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
• Hematuria - Hematuria is visible blood in the urine.
• Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 2-Fluorodeschloroketamine on a daily or even weekly basis and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Benzodiazepines - Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position.
• MAOIs - MAO-B inhibitors appear to increase the potency of ketamine. MAO-A inhibitors have some negative reports associated with the combination but there isn't much information available
• Alcohol - Both substances cause ataxia and bring a very high risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• GHB - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• GBL - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• Opioids - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
• Tramadol - Potential increased risk of seizures.
• Grapefruit - Grapefruit juice significantly increases oral absorption of ketamine. This may result in the user having double the concentration of ketamine in their system compared to normal. The ketamine may also have a longer duration of effect.^[3] It is likely that this property extends to 2F-DCK as well.

• Austria: 2-Fluorodeschloroketamine is illegal to possess, produce and sell under the NPSG. (Neue-Psychoaktive-Substanzen-Gesetz Österreich) ^[4]
• Canada: 2-Fluorodeschloroketamine is not specifically listed in the Controlled Drugs and Substances Act (CDSA) but could be considered controlled under schedule I: "14 Phencyclidine (1-(1-phenylcyclohexyl)piperidine), its salts, derivatives and analogues and salts of derivatives and analogues, including: (1) Ketamine . . ." It could presumably be considered an analogue of PCP due to its structural similarity to ketamine. ^[5]
• Czech Republic: 6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.) ^[6]
• Germany: 2-Fluorodeschloroketamine is controlled under the NpSG (New Psychoactive Substances Act)^[7] as of July 18, 2019.^[8] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.^[9]
• Italy: 2-Fluorodeschloroketamine is a Schedule I (Tabella I) controlled substance.^[10]
• Latvia: 2-Fluorodeschloroketamine is illegal in Latvia.^[11]
• Switzerland: 2-Fluorodeschloroketamine is a controlled substance specifically named under Verzeichnis E.^[12]
• Turkey: 2-Fluorodeschloroketamine is a classed as drug and is illegal to possess, produce, supply, or import.^[13]
• United Kingdom: 2-Fluorodeschloroketamine is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 2-Amino-2-phenylcyclohexanone substituted in the phenyl ring with a halide substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.^[14]

• Responsible use
• Designer drug
• Dissociatives
• Arylcyclohexylamines
• Deschloroketamine (O-PCM)
• MXE

• 2-Fluorodeschloroketamine (Wikipedia)
• 2-Fluorodeschloroketamine (Isomer Design)
• The Big & Dandy 2-Fluoroketamine Thread (Bluelight)